Bristol Myers Squibb Inks Record $15.2B Pharmaceutical Deal with Hengrui

Bristol Myers Squibb announced a landmark strategic collaboration with China-based Hengrui Pharma valued at up to $15.2 billion, representing one of the largest pharmaceutical licensing deals of 2026. Under the agreement, BMY will pay $600 million upfront plus $350 million in near-term milestones ($175M at one year, $175M in 2028), totaling $950 million in committed near-term capital. The partnership spans 13 early-stage programs across oncology, hematology, and immunology — five of which will be jointly discovered and developed, representing a genuine scientific collaboration rather than a straightforward asset acquisition.

The deal grants BMS access to Hengrui's deep pipeline in cancer biology and immune-mediated diseases, while giving Hengrui a pathway to global commercialization through BMS's international infrastructure and regulatory expertise. Hengrui is eligible for tiered royalties on net sales outside its home territory, aligning both parties' incentives across the full commercial lifecycle. The transaction is expected to close in Q3 2026, pending customary regulatory approvals.

For BMY investors, the transaction reflects management's strategy of bolstering the pipeline through early-to-mid-stage partnerships to reduce historical dependence on Revlimid and Opdivo, both facing mounting generic and biosimilar competition. The $15.2B total consideration is predominantly milestone-based, meaning BMS's maximum financial exposure depends on clinical success across all 13 programs — a built-in risk-sharing mechanism. Key watch items are the pace of clinical readouts from the partnered assets and whether Hengrui's early-stage compounds can advance into pivotal trials under BMS's development oversight.

Related Stocks

• BMY